Drug factory · FDA FEI 3003227156

Matrix Pharmacorp Private Limited

Unit 7, Plot No. 14, 99 and 100, IDA, Pashamylaram Phase II, Patancheru, Sangareddy District, Hyderabad, India

India: 1

Problems found, fixed voluntarily at FDA's last inspection, Nov 28, 2025.

Voluntary Action Indicated: inspectors found problems, but not serious enough for FDA to take action. The company is expected to fix them.

6 drug inspections on record since 2009: 1 with no problems, 5 with problems fixed voluntarily, 0 with FDA action.

What it does, for whom

DrugRoleForNDC
DesvenlafaxineMakes the active ingredient IntelliPharmaCeutics Corp. 35208-009, 35208-010
Hydrochlorothiazide and LisinoprilMakes the active ingredient Ranbaxy Laboratories Inc. 63304-536, 63304-537, 63304-538
LisinoprilMakes the active ingredient Ranbaxy Laboratories Inc. 63304-531, 63304-532, 63304-533 +3

FDA inspection history

EndedResultProgramProblems noted
Nov 28, 2025Problems found, fixed voluntarilyDrug Quality Assurance—
Sep 17, 2022Problems found, fixed voluntarilyDrug Quality Assurance—
Dec 30, 2016No problems foundDrug Quality Assurance—
Aug 21, 2015Problems found, fixed voluntarilyDrug Quality Assurance—
Jun 21, 2012Problems found, fixed voluntarilyDrug Quality Assurance—
Apr 3, 2009Problems found, fixed voluntarilyDrug Quality Assurance—

Registered with FDA for: analysis; api manufacture.